glp-1/fgf21 agonist boehringer Transforming obesity: The advancement of multi-receptor drugs: Cell Media Centre | EASD

GLP-1 slows gastric emptying, increases release of insulin when sugar (glucose) is present, suppresses glucagon secretion and therefore liver glucose output, stimulates glucose uptake into cells, and increases proliferation of the cells in the pancreas that make insulin, Rhodes told Healthline

That is very different from saying that informal microdosing has been proven to protect the brain

Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomized controlled trial (LEAD-5 met + SU)

I always explain that this condition is typically temporary

FDA Drug Safety Communication , FDA Warns That DPP4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain accessed July 26, 2023, 166

SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]